80_FR_9769 80 FR 9733 - Anesthetic and Analgesic Drug Products Advisory Committee; Notice of Meeting; Correction

80 FR 9733 - Anesthetic and Analgesic Drug Products Advisory Committee; Notice of Meeting; Correction

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 80, Issue 36 (February 24, 2015)

Page Range9733-9733
FR Document2015-03688

The Food and Drug Administration is correcting a notice entitled ``Anesthetic and Analgesic Drug Products Advisory Committee; Notice of Meeting'' that appeared in the Federal Register of February 6, 2015 (80 FR 6731). The document announced a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The document was published with the incorrect docket number. This document corrects that error.

Federal Register, Volume 80 Issue 36 (Tuesday, February 24, 2015) 
[Federal Register Volume 80, Number 36 (Tuesday, February 24, 2015)]
[Notices]
[Page 9733]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-03688]



[[Page 9733]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-N-0001]


Anesthetic and Analgesic Drug Products Advisory Committee; Notice 
of Meeting; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a notice 
entitled ``Anesthetic and Analgesic Drug Products Advisory Committee; 
Notice of Meeting'' that appeared in the Federal Register of February 
6, 2015 (80 FR 6731). The document announced a forthcoming meeting of a 
public advisory committee of the Food and Drug Administration (FDA). 
The document was published with the incorrect docket number. This 
document corrects that error.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, 
Planning, Legislation, and Analysis, Food and Drug Administration, 
10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993, 
301-796-9115.

SUPPLEMENTARY INFORMATION: In the Federal Register of February 6, 2015, 
in FR Doc. 2015-02408, on page 6731, the following correction is made:
    On page 6731, in the first column, in the Docket No. heading, 
``[Docket No. FDA-2011-N-0824]'' is corrected to read ``[Docket No. 
FDA-2015-N-0001]''.

    Dated: February 17, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-03688 Filed 2-23-15; 8:45 am]
BILLING CODE 4164-01-P

Federal Register / Vol. 80, No. 36 / Tuesday, February 24, 2015 / Notices 9733 DEPARTMENT OF HEALTH AND Name of Committee: Neurological giant wide-neck aneurysms and offer an HUMAN SERVICES Devices Panel of the Medical Devices alternative to other interventional Advisory Committee. techniques or surgery. Food and Drug Administration General Function of the Committee: FDA intends to make background To provide advice and material available to the public no later [Docket No. FDA–2015–N–0001] recommendations to the Agency on than 2 business days before the meeting. Anesthetic and Analgesic Drug FDA’s regulatory issues. If FDA is unable to post the background Products Advisory Committee; Notice Date and Time: The meeting will be material on its Web site prior to the of Meeting; Correction held on April 17, 2015, from 8 a.m. to meeting, the background material will 4 p.m. be made publicly available at the AGENCY: Food and Drug Administration, Location: FDA White Oak Campus, location of the advisory committee HHS. 10903 New Hampshire Ave., Building meeting, and the background material ACTION: Notice; correction. 31 Conference Center, the Great Room will be posted on FDA’s Web site after (rm. 1503), Silver Spring, MD 20993– the meeting. Background material is SUMMARY: The Food and Drug 0002. Answers to commonly asked available at http://www.fda.gov/ Administration is correcting a notice questions including information AdvisoryCommittees/Calendar/ entitled ‘‘Anesthetic and Analgesic Drug regarding special accommodations due default.htm. Scroll down to the Products Advisory Committee; Notice of to a disability, visitor parking, and appropriate advisory committee meeting Meeting’’ that appeared in the Federal transportation may be accessed at: link. Register of February 6, 2015 (80 FR http://www.fda.gov/ Procedure: Interested persons may 6731). The document announced a AdvisoryCommittees/ present data, information, or views, forthcoming meeting of a public AboutAdvisoryCommittees/ orally or in writing, on issues pending advisory committee of the Food and ucm408555.htm. before the committee. Written Drug Administration (FDA). The Contact Person: Jamie Waterhouse, submissions may be made to the contact document was published with the Center for Devices and Radiological person on or before April 3, 2015. Oral incorrect docket number. This Health, Food and Drug Administration, presentations from the public will be document corrects that error. 10903 New Hampshire Ave., Silver scheduled between approximately 10:30 FOR FURTHER INFORMATION CONTACT: Lisa Spring, MD 20993, Jamie.Waterhouse@ a.m. and 11:30 a.m. Those individuals Granger, Office of Policy, Planning, fda.hhs.gov, 301–796–3063, or FDA interested in making formal oral Legislation, and Analysis, Food and Advisory Committee Information Line, presentations should notify the contact Drug Administration, 10903 New 1–800–741–8138 (301–443–0572 in the person and submit a brief statement of Hampshire Ave., Bldg. 32, Rm. 3330, Washington, DC area). A notice in the the general nature of the evidence or Silver Spring, MD 20993, 301–796– Federal Register about last minute arguments they wish to present, the 9115. modifications that impact a previously names and addresses of proposed announced advisory committee meeting participants, and an indication of the SUPPLEMENTARY INFORMATION: In the cannot always be published quickly approximate time requested to make Federal Register of February 6, 2015, in enough to provide timely notice. their presentation on or before March FR Doc. 2015–02408, on page 6731, the Therefore, you should always check the 24, 2015. Time allotted for each following correction is made: Agency’s Web site at http:// presentation may be limited. If the On page 6731, in the first column, in www.fda.gov/AdvisoryCommittees/ number of registrants requesting to the Docket No. heading, ‘‘[Docket No. default.htm and scroll down to the speak is greater than can be reasonably FDA–2011–N–0824]’’ is corrected to appropriate advisory committee meeting accommodated during the scheduled read ‘‘[Docket No. FDA–2015–N–0001]’’. link, or call the advisory committee open public hearing session, FDA may Dated: February 17, 2015. information line to learn about possible conduct a lottery to determine the Leslie Kux, modifications before coming to the speakers for the scheduled open public Associate Commissioner for Policy. meeting. hearing session. The contact person will Agenda: On April 17, 2015, the notify interested persons regarding their [FR Doc. 2015–03688 Filed 2–23–15; 8:45 am] committee will discuss the current request to speak by March 27, 2015. BILLING CODE 4164–01–P knowledge regarding the conduct of Persons attending FDA’s advisory clinical studies and evaluation of committee meetings are advised that the DEPARTMENT OF HEALTH AND clinical study data for flow diverter Agency is not responsible for providing HUMAN SERVICES technology. FDA is convening this access to electrical outlets. committee to seek expert opinion on FDA welcomes the attendance of the Food and Drug Administration scientific and clinical considerations public at its advisory committee relating to the study design and existing meetings and will make every effort to [Docket No. FDA–2015–N–0001] clinical studies, for flow diverter accommodate persons with physical Neurological Devices Panel of the technology indicated for the disabilities or special needs. If you Medical Devices Advisory Committee; neurovasculature. require special accommodations due to Flow diverters are an endoluminal a disability, please contact AnnMarie Notice of Meeting treatment option for intracranial Williams at Annmarie.Williams@ AGENCY: Food and Drug Administration, aneurysms. They are similar to fda.hhs.gov, or 301–796–5966 at least 7 HHS. traditional stents in their tubular metal days in advance of the meeting. tkelley on DSK3SPTVN1PROD with NOTICES ACTION: Notice. structure but with a significantly higher FDA is committed to the orderly mesh density. The working principle is conduct of its advisory committee This notice announces a forthcoming that the high-mesh density reduces flow meetings. Please visit our Web site at meeting of a public advisory committee rate into the aneurysm which promotes http://www.fda.gov/ of the Food and Drug Administration blood stasis and occlusion of the AdvisoryCommittees/ (FDA). The meeting will be open to the aneurysm. Flow diverters are AboutAdvisoryCommittees/ public. advantageous for the treatment of large/ ucm111462.htm for procedures on VerDate Sep<11>2014 17:31 Feb 23, 2015 Jkt 235001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\24FEN1.SGM 24FEN1


Document Created: 2015-12-18 13:22:47
Document Modified: 2015-12-18 13:22:47
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice; correction.
ContactLisa Granger, Office of Policy, Planning, Legislation, and Analysis, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993, 301-796-9115.
FR Citation80 FR 9733 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR